GlassScriptPhysician profile
Gifty Acheampong
NPI 1356989339
$8,175.01
in general payments reported to CMS, 2019-2025
21 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,443 · 2022: $1,901 · 2023: $1,843 · 2024: $1,642 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,830.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,660.28 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,115.98 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $930.25 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $888.27 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $846.75 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $451.42 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $386.71 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Corium, LLC | $336.05 | 2022-2024 | Azstarys |
| Alkermes, INC. | $326.90 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $309.84 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $261.83 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $247.51 | 2021-2025 | Rexulti |
| Tris Pharma INC | $74.20 | 2022-2024 | Dyanavel Xr |
| Indivior INC. | $73.90 | 2023-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $56.48 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $49.67 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $42.22 | 2025 | Cobenfy |
| Almatica Pharma LLC | $41.37 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $40.63 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $18.79 | 2023 | Secuado, Xelstrym |
| Avion Pharmaceuticals | $15.96 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gifty Acheampong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.